Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Iovance Biotherapeutics, Inc.
< Previous
1
2
Next >
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
October 20, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Advanced Mucosal Melanoma at the European Society for Medical Oncology (ESMO) Congress
October 16, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
September 27, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
September 22, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
U.S. Food and Drug Administration Updates Prescription Drug User Fee Act (PDUFA) Action Date for Lifileucel for the Treatment of Advanced Melanoma
September 14, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics to Present at 2023 Wells Fargo Healthcare Conference
September 07, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
August 18, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Second Quarter and First Half 2023 Financial Results and Corporate Updates
August 08, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics to Present Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy at IASLC 2023 World Conference on Lung Cancer
July 25, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, August 8, 2023
July 24, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
July 21, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Announces Closing of $172.5 Million Common Stock Public Offering
July 13, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock
July 10, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock
July 10, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Announces Regulatory and Clinical Updates for TIL Therapy in Advanced Non-Small Cell Lung Cancer
July 10, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics to Host Virtual Roundtable with Key Opinion Leaders to Discuss Melanoma Treatment Landscape
June 20, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics to Present at Jefferies Global Healthcare Conference
June 09, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma
May 26, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
May 09, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, May 9, 2023
May 02, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics to Present at Upcoming Conferences
April 24, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma
March 24, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics to Present at Upcoming Conferences
March 01, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
February 28, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Tuesday, February 28, 2023
February 21, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates
January 23, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics to Present at Upcoming Conferences
November 30, 2022
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma
November 18, 2022
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10, 2022
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 07, 2022
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.